Structure/function studies of an endotoxin-neutralizing peptide derived from bactericidal/permeability-increasing protein

Surgery

Volumn 136, Issue 2, 2004, Pages 253-260

  Wasiluk, Karen R ^a,b   Leslie, Daniel B ^a   Vietzen, Paul S ^a   Mayo, Kevin H ^a   Dunn, David L ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; BACTERIUM LIPOPOLYSACCHARIDE; ENDOTOXIN; NORLEUCINE;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; BACTERICIDAL ACTIVITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DNA FLANKING REGION; DRUG ACTIVITY; HYDROPHOBICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA;

AMINO ACID SEQUENCE; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIA; BLOOD PROTEINS; CELL LINE; LIPOPOLYSACCHARIDES; MEMBRANE PROTEINS; MICE; MOLECULAR SEQUENCE DATA; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3843136392     PISSN: 00396060     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.surg.2004.04.028     Document Type: Article

References (23)

1. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 29:2001;1303-1310
2. Poltorak A., He X., Smirnova I., Liu M.Y., Van Huffel C., Du X., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 282:1998;2085-2088
3. Hoshino K., Takeuchi O., Kawai T., Sanjo H., Ogawa T., Takeda Y., et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol. 162:1999;3749-3752
4. Hack C.E., Aarden L.A., Thijs L.G. Role of cytokines in sepsis. Adv Immunol. 66:1997;101-195
5. Ziegler E.J., Fisher C.J. Jr., Sprung C.L., Straube R.C., Sadoff J.C., Foulke G.E., et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med. 324:1991;429-436
6. Greenman R.L., Schein R.M., Martin M.A., Wenzel R.P., MacIntyre N.R., Emmanuel G., et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA. 266:1991;1097-1102
7. Levin M., Quint P.A., Goldstein B., Barton P., Bradley J.S., Shemie S.D., et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet. 356:2000;961-967
8. Hovde C.J., Gray B.H. Physiological effects of a bactericidal protein from human polymorphonuclear leukocytes on Pseudomonas aeruginosa. Infect Immun. 52:1986;90-95
9. Elsbach P., Weiss J. Role of the bactericidal/permeability-increasing protein in host defence. Curr Opin Immunol. 10:1998;45-49
10. Gray B.H., Haseman J.R. Bactericidal activity of synthetic peptides based on the structure of the 55-kilodalton bactericidal protein from human neutrophils. Infect Immun. 62:1994;2732-2739
11. Beamer L.J., Carroll S.F., Eisenberg D. Crystal structure of human BPI and two bound phospholipids at 2.4 angstrom resolution. Science. 276:1997;1861-1864
12. Battafarano R.J., Dahlberg P.S., Ratz C.A., Johnston J.W., Gray B.H., Haseman J.R., et al. Peptide derivatives of three distinct lipopolysaccharide binding proteins inhibit lipopolysaccharide-induced tumor necrosis factor-alpha secretion in vitro. Surgery. 118:1995;318-324
13. Gray B.H., Haseman J.R., Mayo K.H. B/PI-derived synthetic peptides: synergistic effects in tethered bactericidal and endotoxin neutralizing peptides. Biochim Biophys Acta. 1244:1995;185-190
14. Morrison K.K., Weiss G.A. Combinatorial alanine-scanning. Curr Opin Chem Biol. 5:2001;302-307
15. Spector, S, Wang M, Carp SA, Robblee J, Hendsch AS, Fairman R, et al. Rational modification of protein stability by the mutation of charged surface residues. Biochemistry 39:872-9.
16. Griffioen A.W., van der Schaft D.W.J., Barendsz-Janson A.F., Cox A., Struijker Boudier H.A.J., Hillen H.F.P., et al. Anginex, a designed peptide that inhibits angiogenesis. Biochem J. 354:2001;233-245
17. Mayo K.H., van der Schaft D.W.J., Griffioen A.W. Designed β-sheet peptides that inhibit proliferation and induce apoptosis in endothelial cells. Angiogenesis. 4:2001;45-51
18. Ammons W.S., Kohn F.R., Kung A.H. Protective effects of an N-terminal fragment of bactericidal/permeability-increasing protein in rodent models of gram-negative sepsis: role of bactericidal properties. J Infect Dis. 170:1994;1473-1482
19. 23) decreases Escherichia coli-induced mortality and organ injury during immunosuppression-related neutropenia. Shock. 4:1995;298-306
20. Mayo K.H., Haseman J., Ilyina E., Gray B. Designed beta-sheet-forming peptide 33mers with potent human bactericidal/permeability increasing protein-like bactericidal and endotoxin neutralizing activities. Biochim Biophys Acta. 1425:1998;81-92
21. Uknis M.E., Wasiluk K.R., Acton R.D., Klaerner H.G., Dahlberg P.S., Ilyina E.E., et al. Design of a potent novel endotoxin antagonist. Surgery. 122:1997;380-385
22. van der Schaft D.W.J., Dings R.P.M., De Lussanet Q.G., van Eijk L.I., Nap A.W., Beets-Tam R.G.H., et al. The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models. FASEB J. 16:2002;1991-1993
23. Dings R.P., Arroyo M.M., Lockwood N.A., van Eijk L.I., Haseman J.R., Griffioen A.W., et al. Beta-sheet is the bioactive conformation of the anti-angiogenic anginex peptide. Biochem J. 373:2003;281-288